



ASX ANNOUNCEMENT

Lumos Business Momentum Continues Following ASX Listing

* * * * *

- Lumos expects to exceed its FY21 prospectus revenue forecast by approximately 5% based on unaudited financial results
- Lumos client secures U.S. FDA EUA for rapid, oral COVID-19 antibody test that is manufactured by Lumos
- Medical journal article highlights utility of FebriDx® to support outpatient antibiotic stewardship

MELBOURNE, Australia (2 August 2021): Lumos Diagnostics (ASX: LDX), a leader in rapid point-of-care (POC) diagnostic technologies, has continued to experience strong business momentum following its listing on the ASX in early July. Based on the company's unaudited financial results for FY21, Lumos is on track to exceed its prospectus revenue forecast of AU\$23.7 million by approximately 5%. This reflects an approximately 200% increase in revenue from FY20 driven by an increase in the number and size of client service contracts and new revenue streams from product manufacturing and product sales.

Lumos client, Diabetomics, Inc., a global commercial stage medical diagnostics company, has received an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its CovAb™ SARS-CoV-2 Ab point-of-care COVID-19 antibody test. CovAb™ is the first rapid, oral fluid-based, point-of-care, CLIA-waived antibody test authorised by the FDA for use under an EUA. Unlike other COVID-19 antibody tests that require a blood draw, the CovAb™ test only requires an oral fluid sample obtained with a simple swab of the gumline, making it easy and painless. Lumos provides contract manufacturing of the CovAb™ test at scale for Diabetomics.

A medical journal article¹ published recently in *Clinical Microbiology and Infection*, the official publication of the European Society of Clinical Microbiology and Infectious Diseases, highlighted the important role that the Lumos FebriDx test may play in antibiotic stewardship. The article, titled "Novel point-of-care biomarker combination tests to differentiate acute

¹ Novel point-of-care biomarker combination test to differentiate acute bacterial from viral respiratory tract infections to guide antibiotic prescribing: a systematic review, H.C. Carlton et al (2021), DOI: <https://doi.org/10.1016/j.cmi.2021.05.018>.

bacterial from viral respiratory tract infections to guide antibiotic prescribing: a systematic review,” reports that acute respiratory tract infections are the most common reason that patients seek medical care, with many patients receiving antibiotics inappropriately due to overlapping signs and symptoms of bacterial and viral infections. Antibiotics are ineffective treatment for viral infection. As such, the authors assessed the validity of multiple POC testing methods that can be used to identify bacterial or viral causes of acute respiratory infection. The authors concluded that the FebriDx test shows potential clinical utility in both primary and secondary care settings and specificity that is superior to standalone C-reactive protein (CRP) tests, standalone procalcitonin (PCT) tests and ImmunoXpert (MeMed; Israel).

“FY21 has been a transformational year for Lumos,” said Rob Sambursky, CEO of Lumos Diagnostics. “The business fundamentals for POC diagnostics companies were very strong during FY21 and we undoubtedly experienced some additional momentum for our business driven in part by the COVID-19 pandemic. In addition to our successful listing on the ASX earlier this month, Lumos’ business grew across several different verticals, which resulted in strong revenue from our pipeline of commercial services, initial revenue from the sale of our FebriDx POC diagnostic product and expansion of our manufacturing capacity. We are building momentum and we are positive about our opportunities in FY22.”

This announcement has been approved by the Lumos Disclosure Committee.

###

CovAb™ is a trademark of Diabetomics, Inc.

About Lumos Diagnostics

Lumos Diagnostics specialises in rapid, cost-effective and complete point-of-care (POC) diagnostic test solutions to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customised assay development and manufacturing services for POC tests and proprietary digital reader platforms. Lumos also directly develops, manufactures and commercialises novel Lumos-branded POC tests that target infectious and inflammatory diseases.

For more information on Lumos Diagnostics, visit lumosdiagnostics.com, and for more information on FebriDx, visit febridx.com.

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. These forward-looking statements should be read in conjunction with, and are qualified by reference to, risks

as set out in Section 5 of Lumos prospectus dated 7 June 2021, general assumptions, specific assumptions and the sensitivity analysis as set out in Section 4 of that prospectus, and other information in the announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Important Notices

This announcement has been prepared for publication in Australia and may not be released to U.S. wire services or distributed in the United States. This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any securities described in this announcement have not been, and will not be, registered under the U.S. Securities Act of 1933 and may not be offered or sold in the United States except in transactions exempt from, or not subject to, registration under the U.S. Securities Act and applicable U.S. state securities laws.

Media Contact (Australia):

Haley Chartres – H[^]CK
haley@hck.digital
+61 423 139 163

Media Contacts (U.S. and Global):

Jennifer Christiansen – Lumos Diagnostics
Laura Lovejoy Sambursky – Saranova, LLC
communications@lumosdiagnostics.com
+1 941 928 9025

Investor Contact:

Matthijs Smith – Lumos Diagnostics
ir@lumosdiagnostics.com
+61 411 137 080
+61 3 9087 1598

Company Registered Office:

Lumos Diagnostics Holdings Ltd
Level 4, 100 Albert Rd
South Melbourne, VIC 3205
+61 3 9087 1598